The combination of HER2-targeted antibodies and immunostimulatory antibodies against PD-1 and CD137 demonstrated synergistic preclinical anti-tumor activity, which supported the clinical evaluation of combination therapy with HER2-targeted and PD-(L)1 antibodies [47]. Here, PDCD1 is linked to neoplasm.